KV Pharma CEO Gets Hefty Raise, Despite All The Problems
11:50 EDT 30 Jul 2012 | Forbes
Even as KV Pharmaceutical signals its ability to continue as a going concern remains questionable, its ceo gets a hefty hike in compensation amid a contentious lawsuit with the FDA over its Makena treatment for premature births.
Original Article: KV Pharma CEO Gets Hefty Raise, Despite All The Problems
More From BioPortfolio on "KV Pharma CEO Gets Hefty Raise, Despite All The Problems"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
